Tetrahydropalmatine (Synonyms: DL-Tetrahydropalmatine)

Name: Tetrahydropalmatine
Brand: MedChemExpress
SKU: HY-N0300
Rating: 5.0 (3 reviews)

Cat. No.: HY-N0300 Purity: 99.93%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Tetrahydropalmatine possesses analgesic effects. Tetrahydropalmatine acts through inhibition of amygdaloid release of dopamine to inhibit an epileptic attack in rats.

For research use only. We do not sell to patients.

CAS No. : 2934-97-6

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of Tetrahydropalmatine:

Rotundine In-stock
Tetrahydropalmatine hydrochloride In-stock
Tetrahydropalmatine (Standard) In-stock

3 Publications Citing Use of MCE Tetrahydropalmatine

Bio/Physico-chemical Assay

In Vivo Imaging

Cell Imaging/Staining

IHC

: Tetrahydropalmatine purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2023 Dec 31:169:115887. [Abstract]; High-definition digital photos and Doppler images illustrating flap survival and necrosis areas on days 0 and 7 for both the control and Tetrahydropalmatine (THP, 2 mg/kg) groups.

: Tetrahydropalmatine purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2023 Dec 31:169:115887. [Abstract]; IHC for CD34-positive microvessels in the choke II region of the control and Tetrahydropalmatine (THP) groups (200X); scale bar, 100 µm.

: Tetrahydropalmatine purchased from MedChemExpress. Usage Cited in: J Anim Sci. 2022 Apr 1;100(4):skac069. [Abstract]; The accumulation of spermine or spermidine in boar sperm was inhibited by 60 μmol/L quinidine or 60 μmol/L Tetrahydropalmatine (THP), but neither 60 μmol/L mildronate nor 60 μmol/L l-carnitine.

: Tetrahydropalmatine purchased from MedChemExpress. Usage Cited in: J Anim Sci. 2022 Apr 1;100(4):skac069. [Abstract]; SM-FITC or SD-FITC in the sperm was significantly decreased after the supplementation of 60 μmol/L quinidine or 60 μmol/L Tetrahydropalmatine (THP).

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Dopamine Receptor Isoform Specific Products:

View All Isoforms

Dopamine Receptor D₁ Receptor D₂ Receptor D₃ Receptor D₄ Receptor D₅ Receptor

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

Tetrahydropalmatine possesses analgesic effects. Tetrahydropalmatine acts through inhibition of amygdaloid release of dopamine to inhibit an epileptic attack in rats^[1].

IC₅₀ & Target

Dopamine^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
THP-1	IC₅₀	14.98 nM Compound: 2	Inhibition of tissue factor procoagulant activity in LPS-stimulated human THP1 cells preincubated for 1 hr before LPS addition measured after 5 hrs Inhibition of tissue factor procoagulant activity in LPS-stimulated human THP1 cells preincubated for 1 hr before LPS addition measured after 5 hrs	[PMID: 23199480]

In Vivo

Tetrahydropalmatine (THP), an active component isolated from corydalis (a Chinese herbal medicine), possesses analgesic effects. Picrotoxin treatment alone has a significant effect on the following activity measure: there is an increase in horizontal motion time (HMT), vertical motion time (VMT), clockwise turnings (CT), anticlockwise turning (ACT) and a decrease in freezing time (FT). Tetrahydropalmatine treatment alone causes a decrease in HMT, VMT and total distance traveled (TDT), but an increase in FT. Pretreatment of rats with an i.p. dose of 10 mg/kg or 15 mg/kg of Tetrahydropalmatine significantly attenuates the Picrotoxin-induced enhancement in HMT, VMT, CT, ACT and TDT, as well as reduction in FT. Another 48 rats under urethane anesthesia are randomly divided into six groups, each of eight rats. The s.c. injection of Picrotoxin causes an increase in amygdaloid release of dopamine (DA), while i.p. injection of Tetrahydropalmatine at 10 mg/kg has an insignificant effect on amygdaloid release of DA. Again, the Picrotoxin-induced increase in amygdaloid release of DA is significantly attenuated by pretreatment with Tetrahydropalmatine. The Picrotoxin-induced augmented amygdaloid release of DA is almost completely abolished by pretreatment with Tetrahydropalmatine 30 min before s.c. injection of Picrotoxin^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

355.43

Formula

C₂₁H₂₅NO₄

CAS No.

2934-97-6

Appearance

Solid

Color

White to off-white

SMILES

COC1=CC=C2C(CN3CCC4=CC(OC)=C(OC)C=C4C3C2)=C1OC

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 16.67 mg/mL (46.90 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.8135 mL	14.0675 mL	28.1349 mL
5 mM	0.5627 mL	2.8135 mL	5.6270 mL
10 mM	0.2813 mL	1.4067 mL	2.8135 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.67 mg/mL (4.70 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.67 mg/mL (4.70 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 1.67 mg/mL (4.70 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.93%

Select Batch:

Data Sheet (275 KB) SDS (396 KB)

COA (249 KB) HNMR (276 KB) LCMS (94 KB)

Handling Instructions (2659 KB)

References

[1]. Chang CK, et al. DL-Tetrahydropalmatine may act through inhibition of amygdaloid release of dopamine to inhibit an epileptic attack in rats. Neurosci Lett. 2001 Jul 20;307(3):163-6. [Content Brief]

Animal Administration
^[1]

Rats^[1]
Male Sprague-Dawley rats, weighing 250-320 g, are used in the present study. The animals are housed in a temperature-regulated (22±1°C) room on 12:12 h light/dark cycles with food and water available ad libitum. The light is turned on at 06:00 h and turned off at 18:00 h. At least two major groups of animals are studied. (1) Vehicle-treated rats: received an i.p. injection of 0.9% saline plus Picrotoxin (3-4 mg/kg, s.c.). (2) Tetrahydropalmatine-treated rats: receive an injection of Tetrahydropalmatine (10 mg/kg, i.p.) plus Picrotoxin (3-4 mg/kg, s.c.). The effects of s.c. administration of Picrotoxin or Tetrahydropalmatine on locomotor activity are assessed in unanesthetized rats. On the other hand, the effects of Picrotoxin or Tetrahydropalmatine on amygdaloid DA release are assessed in rats under urethane (1.4 g/kg, i.p.) anesthesia^[1].
Seventy-two unanesthetized rats are randomly divided into nine groups, each of eight rats. The animals are adapted to the behavior apparatus for 30 min before an injection of Picrotoxin (3 or 4 mg/kg, s.c.), Tetrahydropalmatine (10 or 15 mg/kg, i.p.) or saline. Then, the locomotor activities of these rats are recorded during the 30-min period following the injections^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

[1]. Chang CK, et al. DL-Tetrahydropalmatine may act through inhibition of amygdaloid release of dopamine to inhibit an epileptic attack in rats. Neurosci Lett. 2001 Jul 20;307(3):163-6. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.8135 mL	14.0675 mL	28.1349 mL	70.3373 mL
	5 mM	0.5627 mL	2.8135 mL	5.6270 mL	14.0675 mL
	10 mM	0.2813 mL	1.4067 mL	2.8135 mL	7.0337 mL
	15 mM	0.1876 mL	0.9378 mL	1.8757 mL	4.6892 mL
	20 mM	0.1407 mL	0.7034 mL	1.4067 mL	3.5169 mL
	25 mM	0.1125 mL	0.5627 mL	1.1254 mL	2.8135 mL
	30 mM	0.0938 mL	0.4689 mL	0.9378 mL	2.3446 mL
	40 mM	0.0703 mL	0.3517 mL	0.7034 mL	1.7584 mL

Tetrahydropalmatine Related Classifications

Neurological Disease

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Tetrahydropalmatine2934-97-6DL-TetrahydropalmatineDopamine ReceptorApoptosisInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Tetrahydropalmatine (Synonyms: DL-Tetrahydropalmatine)

Customer Review

Other Forms of Tetrahydropalmatine:

Tetrahydropalmatine Related Antibodies

3 Publications Citing Use of MCE Tetrahydropalmatine

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Dopamine Receptor Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Tetrahydropalmatine Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report